Search clinical trials for: ALM201

Total 68 results

Almac Discovery

Terminated

A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours

Ovarian Cancer | Solid Tumors

United Kingdom
UNION therapeutics

Completed

Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD

Atopic Dermatitis

Bulgaria, Denmark, Poland
ValiRx Plc

Completed

Dose Finding Safety Study of VAL201 in Cancer Patients (VAL201-001)

Stage III Prostate Carcinoma | Stage IV Prostate Carcinoma
UNION therapeutics

Completed

Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Impetigo

South Africa
UNION therapeutics

Completed

Sensitization Study of ATx201 in Healthy Volunteers

Sensitivity, Contact

United States
UNION therapeutics

Completed

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

Irritation Potential of Topic Agent

United States
UNION therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis

Canada
Baliopharm Pty Ltd

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers

Healthy Volunteers

Australia
Glycomine, Inc.

Recruiting

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

Pmm2-CDG

Spain, Australia, United States
Freeline Therapeutics

Recruiting

A Gene Therapy Study in Patients With Gaucher Disease Type 1 (GALILEO-1)

Gaucher Disease, Type 1

Spain, Israel, United States, United Kingdom, Brazil, Germany, Paraguay
Novartis Pharmaceuticals

Terminated

A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Allogeneic Stem Cell Transplantation

Italy, Germany, Spain
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

Liposarcoma

France, Taiwan, Germany, Spain, Canada, Singapore
Novartis Pharmaceuticals

Terminated

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

Uveal Melanoma

United States, Australia, France, Netherlands, Spain, Norway
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
InnoBM Pharmaceuticals Co., Ltd.

Recruiting

BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors (BM201-1001)

Advanced Solid Tumors

China
Alector Inc.

Active, not recruiting

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Frontotemporal Dementia

Spain, United States, Portugal, United Kingdom, France, Germany, Netherlands, Belgium, Australia, Italy, Turkey, Switzerland, Argentina, Canada, Greece, Sweden
Novartis Pharmaceuticals

Completed

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Advanced Solid and Hematological TP53wt Tumors

France, Netherlands, Spain, Germany, Singapore, Japan, Taiwan, United States
Ambrx, Inc.
Merck Serono International SA

Completed

Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).

Growth Hormone Deficiency

Hungary
AmDerma

Completed

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Skin Diseases | Skin Diseases, Papulosquamous | Plaque Psoriasis

United States
Centre Leon Berard
Novartis; National Cancer Institute, France

Recruiting

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas (AMPHISARC)

Advanced Soft-tissue Sarcoma | Metastatic Soft-tissue Sarcoma

France
Jetema USA Inc.

Not yet recruiting

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Glabellar Lines
Ayala Pharmaceuticals, Inc,

Terminated

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY)

Triple Negative Breast Cancer

United States, Belgium, Israel, Spain, United Kingdom
Alector Inc.

Active, not recruiting

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

Frontotemporal Dementia

Canada, United States, Germany, United Kingdom, Italy, Netherlands
TScan Therapeutics, Inc.

Recruiting

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Melanoma | Cervical Cancer | Head and Neck Cancer | HPV-Related Malignancy | Ovarian Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Non-small Cell Carcinoma | HPV - Anogenital Human Papilloma Virus Infection | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma and other conditions

United States
Ayala Pharmaceuticals, Inc,

Completed

A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY)

Adenoid Cystic Carcinoma

United States, Canada, France, United Kingdom, Israel, Netherlands
AnnJi Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

Spinal and Bulbar Muscular Atrophy | Kennedy's Disease

United States
Alector Inc.
GlaxoSmithKline

Enrolling by invitation

Continuation Study for Latozinemab

Neurodegenerative Diseases

Canada, United States, Belgium, France, Spain, Portugal, Germany, Italy, Netherlands, Sweden, United Kingdom
Alector Inc.

Terminated

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Amyotrophic Lateral Sclerosis

United States
Aimmune Therapeutics, Inc.

Terminated

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Hen Egg Allergy

United States
DEXLEVO

Completed

To Prove the Non-inferiority of DLMR01 by Evaluating the Injecting Efficacy and Safety DLMR01 and Control for Patients in Crow's Feet (dermal filler)

Crow's Feet Lines

Korea, Republic of
Apeiron Biologics

Completed

Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer

Radiation Induced Dermatitis

Austria
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer (mCRPC)

China
M.D. Anderson Cancer Center

Recruiting

AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

Adenoid Cystic Carcinoma | Metastatic Adenoid Cystic Carcinoma

United States
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States, China
Novartis Pharmaceuticals

Active, not recruiting

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)

Myelofibrosis

United Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
Alector Inc.

Completed

A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

Healthy

United States
Rocket Pharmaceuticals Inc.
California Institute for Regenerative Medicine (CIRM)

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

Leukocyte Adhesion Defect - Type I

Spain, United States, United Kingdom
Rocket Pharmaceuticals Inc.

Withdrawn

A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

Leukocyte Adhesion Defect - Type I

Spain
UNION therapeutics

Completed

Evaluation of ATx201 as a Topical Antibiotic Agent

Infection, Bacterial

Austria
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study YL201 in Patients With Selected Advanced Solid Tumors

Advanced Solid Tumor

China
Children's Hospital of Philadelphia

Not yet recruiting

ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia

Beta-Thalassemia

United States
Armgo Pharma, Inc.
Food and Drug Administration (FDA)

Recruiting

Treatment of an Inherited Ventricular Arrhythmia

Catecholaminergic Polymorphic Ventricular Tachycardia Type 1

United States, Netherlands
Novartis Pharmaceuticals

Active, not recruiting

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Spain, Singapore, Australia, Germany, Italy, Finland, United States
Alector Inc.

Completed

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

Healthy | Frontotemporal Dementia

United States, Canada, United Kingdom
Kitasato University
Aetas Pharma Co. Ltd.

Unknown

First-in-Patient Study for Sing le Dose of M201-A Hydrochloride Injection in Japanese Patients With Paroxysmal Atrial Fibrillation

Paroxysmal Atrial Fibrillation

Japan
AmDerma

Completed

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

Actinic Keratosis

United States
AmDerma
International Dermatology Research, Inc.

Completed

Safety and Efficacy Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque Psoriasis

Plaque Psoriasis

Dominican Republic
Lux Biosciences, Inc.

Terminated

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

Corneal Diseases | Cornea Transplant

United States, Germany
Lux Biosciences, Inc.

Terminated

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

Corneal Transplantation | Corneal Graft Rejection

United States, Germany
Yuji KUMAGAI
Aetas Pharma Co. Ltd.

Completed

First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects

Healthy Volunteers

Japan

Search clinical trials for: ALM201

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations